|   | A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malign...A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors - Full ...  |  
  |  
  | 
Conditions:   Malignancy;   Non-hodgkin Lymphoma;   Multiple Myeloma;   Breast Cancer;   Ovarian Cancer;   Soft Tissue Sarcoma;   Squamous Cell Carcinoma;   Head and Neck Cancer;   DLBCL;   Mantle Cell Lymphoma;   Follicular Lymphoma;   Leiomyosarcoma;   Pancreatic Cancer;   Sarcoma;   CLLIntervention:   Drug: CYT-0851Sponsor:   Cyteir Therapeutics, Inc.Not yet recruiting
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου